clinical trial · NCT06617572
Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
USWM CT, LLC·—·available
Synovial SarcomaMyxoid LiposarcomaNon-conforming afamitresgene autoleucel
brief summary
The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel). This EAP will be conducted at authorized treatment centers where TECELRA® is being administered and where the EAP is approved to be conducted. Patients who are prescribed TECELRA® , sign the informed consent form, and meet all entry criteria will be eligible to participate in this protocol.
started
—
primary completion
—
completion
—
last updated
Feb 9, 2026
official title
Expanded Access Protocol for Product Which Does Not Conform to the TECELRA® (Afamitresgene Autoleucel, Suspension for Intravenous Infusion) Commercial Release Specification
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol